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Abstract
Objective
After the recent publication of the first patients with disease-associated missense variants in the
GRIN2D gene, we evaluate the effect of copy number variants (CNVs) overlapping this gene
toward the presentation of neurodevelopmental disorders (NDDs).
Methods
We exploredClinVar (number ofCNVs = 50,794) andDECIPHER (number of CNVs = 28,085)
clinical databases of genomic variations for patients with copy number changes overlapping the
GRIN2D gene at the 19q13.33 locus and evaluated their respective phenotype alongside their
frequency, gene content, and expression, with publicly available reference databases.
Results
We identified 11 patients with microduplications at the 19q13.33 locus. The majority of CNVs
arose de novo, and comparable CNVs are not present in control databases. All patients were
reported to have NDDs and dysmorphic features as the most common clinical phenotype (N =
8/11), followed by seizures (N = 6/11) and intellectual disability (N = 5/11). All duplications
shared a consensus region of 405 kb overlapping 13 genes. After screening for duplication
tolerance in control populations, positive gene brain expression, and gene dosage sensitivity
analysis, we highlight 4 genes for future evaluation: CARD8, C19orf68, KDELR1, andGRIN2D,
which are promising candidates for disease causality. Furthermore, investigation of the litera-
ture especially supports GRIN2D as the best candidate gene.
Conclusions
Our study presents dup19q13.33 as a novel duplication syndrome locus associated with NDDs.
CARD8, C19orf68, KDELR1, and GRIN2D are promising candidates for functional follow-up.
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NMDA receptors are involved in neurodevelopmental
processes such as synaptogenesis, learning, and memory.
Structurally, NMDA receptors are composed of 2 subunits
of GluN1 and GluN2, which are specifically encoded by the
GRIN1 and GRIN2A to GRIN2D genes, respectively.1
While single nucleotide and copy number variants (CNVs)
in the NMDA receptor subunits GRIN1, GRIN2A, and
GRIN2B have been associated with a range of neuro-
developmental disorders (NDDs), little is known about the
association of GRIN2D variants and NDDs. Recently, de
novo missense mutations in GRIN2D (p.Val667Ile) have
been identified as the cause of severe epileptic encepha-
lopathy2 in 2 independent patients. However, whether
CNVs covering the GRIN2D locus are also associated with
disease has not been studied. GRIN2D is encoded at the
end of the long arm of chromosome 19 at the 19q13.33
locus. We hypothesize that dosage changes in GRIN2D are
highly likely to be disease associated based on the high
sequence homology, expression during neurodevelopment,
and a functional relationship with the established disease-
associated paralogous genes.
Methods
Standard protocol approvals, registrations,
and patient consents
We obtained approval from an ethical standards committee
on human experimentation (institutional or regional) for any
experiments using human subjects. Written informed consent
was obtained from all patients (or guardians of patients)
participating in the study (consent for research), following the
guidelines provided by ClinVar and DECHIPER databases.
We obtained authorization for disclosure (consent to dis-
close) of the photograph that may be published in the journal,
in derivative works by the AAN, or on the journal’s website.
Data analysis
Using the gene-oriented query “GRIN2D,” we accessed 2
publicly available repositories of clinical genetic variation: (1)
The Database of Chromosomal Imbalance and Phenotype in
Humans using Ensembl Resources, DECIPHER3 (URL:
https://decipher.sanger.ac.uk, accessed on July 2016) and (2)
The public archive of interpretations of clinically relevant var-
iants, ClinVar4 (URL: http://www.ncbi.nlm.nih.gov/clinvar,
accessed on July 2016). For DECIPHER patients, the individual
scientists were contacted to acquire further phenotype in-
formation including the presence of intellectual disability (ID),
developmental delay (DD), seizures, hypotonia, dysmorphism
(Dysm), learning difficulties, behavioral problems as well as
social communication, and behavioral disorders of the autism
spectrum disorder.5 We considered only DECIPHER entries
with positive submitter contact. All phenotypes evaluated were
considered as binary denominators (i.e., Yes/No). Gene
annotations of the extracted CNVs refer to the genome build
GRCh37/hg19. A consensus region was determined with an in-
house Python script (available on request). Genes inside the
consensus region were further evaluated as disease candidate
genes with additional publicly available resources for (1) brain
expression, strongly brain-expressed genes (n = 4,756), speci-
fied by a log (RPKM) >4.5 of the BrainSpan RNA.Seq tran-
scriptome data set6; (2) overlapping CNVs reported in the
curated control inclusive map of the Database of Genomic
Variants7; (3) loss-of-function (LoF) intolerance reported in the
Exome Aggregation Consortium,8 given by a probability of
being LoF intolerant (pLI score) equal to or greater than 0.9
based on the observed genetic variation of 60,706 healthy
individuals; and (4) overlapping CNVs reported in 20,227
controls.9 Genome-wide brain-specific noncoding functional
elements were extracted from the GenoSkyline; project
(http://genocanyon.med.yale.edu/GenoSkyline), which
implements a statistical framework based on high-throughput
genetic and epigenetic data to predict tissue-specific func-
tional noncoding elements.10
Results
We detected 11 patients with CNVs overlapping the 19q13.33
locus (table 1). Of interest, all of themwere duplications. Three
were annotated in ClinVar (patients 1 through 3) and 8 in
DECIPHER (patients 4 through 11). Although a ninth in-
dividual did fulfill the inclusion criteria (DECIPHER entry
275388), given the actual size of the reported variant in com-
parison with the entire chromosome 19 (CNV = 58.83 Mb vs
Chr19 = 59.12 Mb), it was considered a chromosome trisomy
and therefore was excluded. Detailed clinical phenotypes are
provided in table 1. Notably, all patients were reported to have
mild to severe forms of NDDs. Of all the phenotypes evaluated,
mild but distinct dysmorphic features were the most frequent
(n = 8), followed by seizures (n = 6, including generalized tonic
and febrile seizures), ID (n = 5), and DD (n = 4). In particular,
dysmorphisms were present in patients carrying CNVs larger
than 3 Mb (pathogenic size according to the American College
of Human Genetics). The image of 1 of such patients is shown
in figure, A, showing a child with signs of macrostomia, mid-
face hypoplasia, and progenia.
For DECIPHER entries with available parental information,
85.7% (n = 6) of observed microduplications were de novo,
and only 1 was inherited from an affected family member.
The majority of (87.5%, n = 7) patients did not carry addi-
tional CNVs, and none of the additional CNVs found in 3
patients covered a known disease locus or known disease
Glossary
DD = developmental delay; ID = intellectual disability; LoF = loss of function; NDD = neurodevelopmental disorder.
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Table 1 Clinical phenotypes of the 11 retrieved patients with GRIN2D variants at the 19q13.33 locus
Patient Resource
Database entry
ID
Size
(Mb) Sex
Type of
variant
De
novo
No
CNVs ID DD Seizures Hypotonia ASD Dysm
Learning
difficulties
Behavioral
problems
1 ClinVar 59117 10.65 — Gain — — — Yes Yes — — Yes — —
2 ClinVar 59116 10.64 — Gain — — — Yes* — — — ? — —
3 ClinVar 59115 2.39 — Gain — — — — Yes — — — — —
4 DECIPHER 257554 0.91 M Gain No** 1 — — Yes — — — Yes —
5 DECIPHER 262506 2.51 F Gain Yes 1 Yes Yes Yes Yes — Yes Yes —
6 DECIPHER 269407 3.57 M Gain Yes 1 Yes — — — — Yes — —
7 DECIPHER 274058 10.64 F Gain Yes 1 Yes — Yes — — Yes — Yes
8 DECIPHER 275426 7.78 F Gain Yes 1 — Yes Yes Yes — Yes — —
9 DECIPHER 282304 2 F Gain — 2 — Yes — — — Yes — —
10 DECIPHER 282364 2.72 F Gain Yes 1 Yes — — — — Yes Yes —
11 DECIPHER 328426 1.16 F Gain Yes 1 Yes — — — — Yes — —
Literature Patient Size (Mb) Sex Type of variant De novo No CNVs ID DD Seizures Hypotonia ASD Dysm Learning difficulties Behavioral problems
12 Dorn et al.13 [1] 15.7 M Gain — 1 Yes Yes Yes — — Yes — —
13 Dorn et al.13 [2] 15.7 F Gain — 1 Yes — Yes — — Yes — —
14 Carvalheira et al.11 [1] 10.6 F Gain Yes 1 Yes Yes Yes — — Yes Yes —
15 Wang et al.12 [1] 1.22 — Gain — 1 — — Yes — — — — —
16 Wang et al.12 [5] 1.22 — Gain — 1 — — Yes — — — — —
17 Wang et al.12 [7] 1.22 — Gain — 1 — — Yes — — — — —
GRIN2D pathogenic SNV Patient Mutation Sex Effect De novo No CNVs ID DD Seizures Hypotonia ASD Dysm
Learning
difficulties
Behavioral
problems
18 Li et al.2 [1] p.
Val667Ile
Gain of function Yes — — Yes Yes Yes — Yes Yes —
19 Li et al.2 [2] p.
Val667Ile
Gain of function Yes — — Yes Yes Yes — — Yes —
Abbreviations: ? = not clear; * = developmental delay and/or other significant developmental or morphological phenotypes; ** = from affected parent; ASD = autism spectrum disorder; DD = developmental delay; Dysm =
dysmorphism; ID = intellectual disability; No CNVs = number of copy number variants annotated in patient; P = patient; SNV = single nucleotide variant.
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genes. All 11 CNVs were highly heterogeneous in their size
(average = 4.99 Mb; SD = 4.05 Mb) and breakpoint distri-
bution (encompassing from Chr19: 45.38 Mb–59.09 Mb,
Hg19) (table 1).
To identify additional CNVs absent in ClinVar and/or
DECIPHER databases, we screened the literature and
retrieved 3 additional studies, including 6 patients with
duplications at the 19q13.33 locus.11–13 All of these patients
had seizures. Three patients carried CNVs of 1.22 Mb size,
whereas the remaining 3 duplications were >10 Mb.
Patients affected by the large CNVs were, in addition to
seizures, also affected by other NDDs including ID and
dysmorphism.
FigureGenomic and facial overview of themicroduplications overlapping the GRIN2D gene found in the retrieved patients
(A) Clinical anteroposterior facial photograph of patient 10 depicting characteristic facial features. (B) Thirteen patients were identified with GRIN2D
duplications at the 19q13.33 locus. Blue horizontal bars represent the respective microduplication size and breakpoints according to GRCh37/hg19 human
genome reference in a 12-Mb genomic window. Gray horizontal bars represent the respective microduplication reported in the study by Dorn et al.13
Carvalheira et al.11 andWang et al.12 in which no exact copy number variant boundaries are specified (*). Microduplications larger than the depicted genomic
interval are shownwith arrows at boundaries (patients 1, 2, 7, and 8). Bottom panel: The consensus duplicated region of the 12 patients is depicted in the blue
horizontal bar in a 405-kb window. Thirteen RefSeq genes are located in this region.
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Of interest, the 2 independent patients with the p.Val667Ile
mutation on GRIN2D featured similar NDDs including
DD, dysmorphism, seizures, and muscular hypotonia
(table 1).
Overall, the consensus duplicated region was determined to
be located within the coordinates 48,520,809 bp–48,926,006
bp, with a final size of 405 kb. This is consistent with previous
reports.11–13 The consensus region overlapped 13 RefSeq
genes (figure, B) that were further examined for brain ex-
pression, the presence of CNVs overlapping these genes in
control cohorts, and variation intolerance (table 2). Four
genes persisted above all available filters, namely, the caspase
recruitment domain family member 8 (CARD8), the chro-
mosome 19 open reading frame 68 (C19orf68), the
KDEL endoplasmic reticulum protein retention receptor 1
(KDELR1), and the glutamate ionotropic receptor NMDA
type subunit 2D (GRIN2D). In our view, these 4 genes rep-
resent the most promising candidates.
We also searched for noncoding brain-specific functional
elements within the consensus region. A total of 291 were
found overlapping 9.87% of the consensus region (40,019
bp). Within the consensus regions of the duplications, the
density of noncoding elements was not significantly higher
than that outside of chromosome 19.
Discussion
Here, we report on 11 patients with duplications at a potential
novel disease locus within 19q13.33. Several lines of evidence
support the hypothesis that duplications at this locus are as-
sociated with NDDs: (1) duplications at this locus are virtually
absent in healthy individuals from the general population8; (2)
all of the identified duplications with parental information arose
de novo with the exception of patient 4, which according to
DECIPHER was inherited from an affected parent with a sim-
ilar phenotype (DECIPHER entry 257554); (3) none of the
patients carried additional likely pathogenic CNVs; and (4)
all duplications covered multiple plausible disease candidate
genes.
The NDDs observed in the 11 patients were characterized by
dysmorphism as the most prominent feature, followed by ID
and seizures (table 1). Our observations are in agreement with
previous reports.11–13 Although, 1 example12 focused exclu-
sively on seizures, we cannot rule out that other NDDs were
actually present in those patients. Similarly, we acknowledge
that DD, behavioral problems, and learning difficulties may be
subject to interobserver variability to some extent. In this
regard, future clinical studies of 19q13.33 duplication carriers
need to be conducted to draw detailed and robust genotype-
phenotype conclusions. Since previous reports from the
Table 2 Consensus region gene annotation and candidate gene filtering
Transcipt ID chrom cdsStart cdsEnd Gene
Size
(pb)
Brain
expressed?a
DGV
[clean]
CNVs not
present in
controls?b
ExAC LoF
Intolerance?c
PCG
Browser
CNV not
present in
controls?d Total
NM_022142 chr19 48,511,924 48,525,584 ELSPBP1 13,660 No Yes No Yes 2/4
NM_019855 chr19 48,533,813 48,547,179 CABP5 13,366 No Yes No Yes 2/4
NM_001159322 chr19 48,551,599 48,613,772 PLA2G4C 62,173 Yes No Yes Yes 3/4
NM_001320971 chr19 48,618,905 48,668,823 LIG1 49,918 Yes Yes Yes No 3/4
NM_199341 chr19 48,675,059 48,700,084 C19orf68 25,025 Yes Yes NA Yes 3/3
NM_014959 chr19 48,714,966 48,744,277 CARD8 29,311 Yes Yes Yes Yes 4/4
NM_153608 chr19 48,783,056 48,790,135 ZNF114 7,079 No Yes No Yes 2/4
NM_144577 chr19 48,800,232 48,822,028 CCDC114 21,796 Yes Yes No Yes 3/4
NM_001313905 chr19 48,830,101 48,833,727 EMP3 3,626 Yes Yes No Yes 3/4
NM_018273 chr19 48,836,475 48,867,177 TMEM143 30,702 Yes No Yes Yes 3/4
NM_012451 chr19 48,869,099 48,879,575 SYNGR4 10,476 No Yes Yes Yes 3/4
NM_006801 chr19 48,886,549 48,894,615 KDELR1 8,066 Yes Yes Yes Yes 4/4
NM_000836 chr19 48,901,649 48,947,194 GRIN2D 45,545 Yes Yes Yes Yes 4/4
aBrain-expressed genes from Uddin et al.6
bDGV curated CNV control map from Zarrei et al.7
cExAC LoF Intolerant genes from Lek et al.8
dPCG Control CNVs from Marshall et al.9
Bold genes are positive in all applicable filters and are highlighted as “candidates genes” for future evaluation.
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literature were based on low-resolution cytogenetic meth-
ods,13 identification of the underlying disease gene was not
possible. Here, we show that by integration of multiple CNVs
data sets from public repositories, we are able to narrow down
the disease-associated genomic sequence to a few candidate
genes at the 19q13.33 locus (figure).
Our included data sets do not allow estimation of 19q13.33
duplication frequency. However, the absence of 19q13.33
duplications in CNVs databases of the general population and
the presence of only a few variant carrying patients in diagnostic
CNVs databases with heterogeneous breakpoints indicate that
19q13.33 duplications are extremely rare (table 2).
All 11 of the identified patient CNVs shared a genomic in-
terval of 405 kb, which includes 4 genes with genetic, pop-
ulation and biological support of disease association. These
included CARD8, C19orf68, KDELR1, and GRIN2D. For
CARD8, C19orf68, and KDELR1, no association with NDDs
has been reported in the literature to date. Although we
cannot rule out that brain-specific noncoding elements at
19q13.33 could be involved in the development of NDDs,
GRIN2D represents a plausible candidate gene for associa-
tion with NDDs. GRIN2D, encoding the NMDA receptor
subunit GluN2D, is highly expressed prenatally and after
birth before progressively declining through adulthood.14 It
is possible that GRIN2D microduplications may predispose
to disease susceptibility in a dose-dependent manner by
enhancing GluN2D expression during development, thereby
influencing the NMDA receptor composition, which might
provoke changes in neuronal networks, thus contributing to
hyperexcitability and neurologic diseases.15 Besides CNVs,
the GRIN2D gene is also depleted due to negative selection
of missense and truncating variants in the general pop-
ulation, supporting theGRIN2D association with disease.8 In
agreement, 2 recently identified GRIN2D single nucleotide
variants also lead functionally to a gain-of-function mutation
in 2 patients with similar outcomes2 (table 1). Beyond the
potential diagnostic relevance, our identification of GRIN2D
as a possible new NDD gene has a potential clinical appli-
cation, since memantine, a low-affinity therapeutic NMDA
channel blocker, selectively blocks extrasynaptic NMDA
receptors that are likely to contain GluN2C/2D subunits.16
This might especially be relevant for patients with gain-of-
function mutations or microduplications.2
Author contributions
Eduardo Pe´rez-Palma: analysis and interpretation of data and
wrote the manuscript. Elmo Saarentaus: analysis and in-
terpretation of clinical data. Giancarlo V. De Ferrari: critical
revision of the manuscript for intellectual content. Marie
Ravoet, Giancarlo V. De Ferrari, Peter Nu¨rnberg, and Ber-
trand Isidor: clinical and critical revision of the manuscript for
intellectual content. Bernd A. Neubauer: drafting of the
manuscript and critical revision of the manuscript for in-
tellectual content. Dennis Lal: study concept and design,
analysis and interpretation of data, and wrote the manuscript.
Acknowledgment
The authors thank all the clinicians, patients, and their
families. This study makes use of data generated by the
DECIPHER community. A full list of centers who con-
tributed to the generation of the data is available from
http://decipher.sanger.ac.uk and via email from decipher@
sanger.ac.uk. Funding for the project was provided by the
Wellcome Trust.
Study funding
Eduardo Pe´rez-Palma was supported by the Chilean Fondo
Nacional deDesarrolloCient´ıfico yTecnolo´gico (FONDECYT)
regular grant number 1140353 to Giancarlo V. De Ferrari.
Dennis Lal received funds from the German Academic Ex-
change Service (DAAD), grant number 57073880. Bernd A.
Neubauer received funding from the Deutsche For-
schungsgemeinschaft (Ne 416/5-1).
Disclosure
E. Pe´rez-Palma has received research support from Fondo
Nacional de Ciencia y Tecnolog´ıa (FONDECYT), Chile.
E. Saarentaus has received research support from the In-
stitute for Molecular Medicine Finland (FIMM) and Sven-
ska Studiefonden. M. Ravoet has been involved in clinical
procedures/imaging studies at the Center of Human Ge-
netics, Cliniques Universitaires St-Luc (10%), 2016. G.V. De
Ferrari has received research support from Fondo Nacional
de Ciencia y Tecnolog´ıa (FONDECYT), Chile, and CON-
ICYT. Chile. P. Nuernberg is a founder, CEO, and share-
holder of ATLAS Biolabs GmbH (ATLAS Biolabs GmbH is
a service provider for genomic analyses). B. Isidor reports no
disclosures. B. Neubauer has served on the scientific advisory
boards of and has received travel funding/speaker honoraria
from Eisai, Bial, and UCB Pharma; has served on the edi-
torial board of Neuropediatrics; and has received research
support from DFG 416/5-1 (German national funding
agency). D. Lal reports no disclosures. Full disclosure form
information provided by the authors is available with the full
text of this article at Neurology.org/NG.
Received August 17, 2017. Accepted in final form September 11, 2017.
References
1. van Zundert B, Yoshii A, Constantine-Paton M. Receptor compartmentalization and
trafficking at glutamate synapses: a developmental proposal. Trends Neurosci 2004;
27:428–437.
2. Li D, Yuan H, Ortiz-Gonzalez XR, et al. GRIN2D recurrent de novo dominant
mutation causes a severe epileptic encephalopathy treatable with NMDA receptor
channel blockers. Am J Hum Genet 2016;99:802–816.
3. Firth HV, Richards SM, Bevan AP, et al. DECIPHER: database of chromosomal
imbalance and phenotype in humans using Ensembl resources. Am J Hum Genet
2009;84:524–533.
4. Landrum MJ, Lee JM, Benson M, et al. ClinVar: public archive of interpretations of
clinically relevant variants. Nucleic Acids Res 2016;44:D862–D868.
5. Battle DE. Diagnostic and statistical manual of mental disorders (DSM). Codas 2013;
25:191–192.
6. Uddin M, Tammimies K, Pellecchia G, et al. Brain-expressed exons under purifying
selection are enriched for de novo mutations in autism spectrum disorder. Nat Genet
2014;46:742–747.
7. Zarrei M, MacDonald JR, Merico D, Scherer SW. A copy number variation map of the
human genome. Nat Rev Genet 2015;16:172–183.
8. Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation
in 60,706 humans. Nature 2016;536:285–291.
6 Neurology: Genetics | Volume 4, Number 1 | February 2018 Neurology.org/NG
9. Marshall CR, Howrigan DP, Merico D, et al. Contribution of copy number variants to
schizophrenia from a genome-wide study of 41,321 subjects. Nat Genet. 2017;49:
27–35.
10. Lu Q, Powles RL, Wang Q, He BJ, Zhao H. Integrative tissue-specific functional
annotations in the human genome provide novel insights on many complex traits and
improve signal prioritization in genome wide association studies. PLoS Genet 2016;
12:e1005947.
11. Carvalheira G, Oliveira MM, Takeno S, Lima FT, Meloni VA, Melaragno MI.
19q13.33–>qter trisomy in a girl with intellectual impairment and seizures. Meta gene
2014;2:799–806.
12. Wang D, Li X, Jia S, et al. Copy number variants associated with epilepsy from gene
expression microarrays. J Clin Neurosci 2015;22:1907–1910.
13. Dorn T, Riegel M, Schinzel A, Siegel AM, Kramer G. Epilepsy and trisomy 19q–
different seizure patterns in a brother and a sister. Epilepsy Res 2001;47:119–126.
14. Paoletti P, Bellone C, Zhou Q. NMDA receptor subunit diversity: impact on receptor
properties, synaptic plasticity and disease. Nat Rev Neurosci 2013;14:383–400.
15. Lemke JR, Lal D, Reinthaler EM, et al. Mutations in GRIN2A cause idiopathic focal
epilepsy with rolandic spikes. Nat Genet 2013;45:1067–1072.
16. Wu YN, Johnson SW. Memantine selectively blocks extrasynaptic NMDA receptors
in rat substantia nigra dopamine neurons. Brain Res 2015;1603:1–7.
Neurology.org/NG Neurology: Genetics | Volume 4, Number 1 | February 2018 7
DOI 10.1212/NXG.0000000000000210
2018;4; Neurol Genet 
Eduardo Pérez-Palma, Elmo Saarentaus, Marie Ravoet, et al. 
Duplications at 19q13.33 in patients with neurodevelopmental disorders
This information is current as of January 29, 2018
Services
Updated Information &
 http://ng.neurology.org/content/4/1/e210.full.html
including high resolution figures, can be found at:
References
 http://ng.neurology.org/content/4/1/e210.full.html##ref-list-1
This article cites 16 articles, 0 of which you can access for free at: 
Subspecialty Collections
 http://ng.neurology.org//cgi/collection/ion_channel_gene_defects
Ion channel gene defects
 http://ng.neurology.org//cgi/collection/developmental_disorders
Developmental disorders
 http://ng.neurology.org//cgi/collection/all_epilepsy_seizures
All Epilepsy/Seizures
following collection(s): 
This article, along with others on similar topics, appears in the
  
Permissions & Licensing
 http://ng.neurology.org/misc/about.xhtml#permissions
its entirety can be found online at:
Information about reproducing this article in parts (figures,tables) or in
  
Reprints
 http://ng.neurology.org/misc/addir.xhtml#reprintsus
Information about ordering reprints can be found online:
reserved. Online ISSN: 2376-7839.
Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights
an open-access, online-only, continuous publication journal. Copyright Copyright © 2018 The Author(s). 
is an official journal of the American Academy of Neurology. Published since April 2015, it isNeurol Genet 
